These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 19956877)
1. Etoposide induces growth arrest and disrupts androgen receptor signaling in prostate cancer cells. Liu S; Yamauchi H Oncol Rep; 2010 Jan; 23(1):165-70. PubMed ID: 19956877 [TBL] [Abstract][Full Text] [Related]
2. Camptothecin disrupts androgen receptor signaling and suppresses prostate cancer cell growth. Liu S; Yuan Y; Okumura Y; Shinkai N; Yamauchi H Biochem Biophys Res Commun; 2010 Apr; 394(2):297-302. PubMed ID: 20206136 [TBL] [Abstract][Full Text] [Related]
3. Hinokitiol, a metal chelator derived from natural plants, suppresses cell growth and disrupts androgen receptor signaling in prostate carcinoma cell lines. Liu S; Yamauchi H Biochem Biophys Res Commun; 2006 Dec; 351(1):26-32. PubMed ID: 17055455 [TBL] [Abstract][Full Text] [Related]
4. Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts. Chiu FL; Lin JK Prostate; 2008 Jan; 68(1):61-71. PubMed ID: 18008333 [TBL] [Abstract][Full Text] [Related]
5. Suppression of androgen receptor expression by dibenzoylmethane as a therapeutic objective in advanced prostate cancer. Jackson KM; Frazier MC; Harris WB Anticancer Res; 2007; 27(3B):1483-8. PubMed ID: 17595765 [TBL] [Abstract][Full Text] [Related]
6. A differential ligand-mediated response of green fluorescent protein-tagged androgen receptor in living prostate cancer and non-prostate cancer cell lines. Nakauchi H; Matsuda K; Ochiai I; Kawauchi A; Mizutani Y; Miki T; Kawata M J Histochem Cytochem; 2007 Jun; 55(6):535-44. PubMed ID: 17312014 [TBL] [Abstract][Full Text] [Related]
7. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1. Zaia A; Fraizer GC; Piantanelli L; Saunders GF Anticancer Res; 2001; 21(1A):1-10. PubMed ID: 11299720 [TBL] [Abstract][Full Text] [Related]
8. Androgen receptor activity is inhibited in response to genotoxic agents in a p53-independent manner. Mantoni TS; Reid G; Garrett MD Oncogene; 2006 May; 25(22):3139-49. PubMed ID: 16434973 [TBL] [Abstract][Full Text] [Related]
9. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214 [TBL] [Abstract][Full Text] [Related]
10. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells. Murthy S; Agoulnik IU; Weigel NL Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350 [TBL] [Abstract][Full Text] [Related]
11. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells. Xie Y; Wolff DW; Lin MF; Tu Y Mol Pharmacol; 2007 Jul; 72(1):73-85. PubMed ID: 17430995 [TBL] [Abstract][Full Text] [Related]
12. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP). Koochekpour S; Lee TJ; Wang R; Culig Z; Delorme N; Caffey S; Marrero L; Aguirre J Prostate; 2007 Feb; 67(2):178-89. PubMed ID: 17044040 [TBL] [Abstract][Full Text] [Related]
13. Interaction of IGF signaling and the androgen receptor in prostate cancer progression. Wu JD; Haugk K; Woodke L; Nelson P; Coleman I; Plymate SR J Cell Biochem; 2006 Oct; 99(2):392-401. PubMed ID: 16639715 [TBL] [Abstract][Full Text] [Related]
14. A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells. Recchia AG; Musti AM; Lanzino M; Panno ML; Turano E; Zumpano R; Belfiore A; Andò S; Maggiolini M Int J Biochem Cell Biol; 2009 Mar; 41(3):603-14. PubMed ID: 18692155 [TBL] [Abstract][Full Text] [Related]
15. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA). Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076 [TBL] [Abstract][Full Text] [Related]
16. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells. Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430 [TBL] [Abstract][Full Text] [Related]
17. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms. Tepper CG; Vinall RL; Wee CB; Xue L; Shi XB; Burich R; Mack PC; de Vere White RW Prostate; 2007 Apr; 67(5):521-35. PubMed ID: 17252539 [TBL] [Abstract][Full Text] [Related]
18. The androgen receptor and prostate cancer invasion. Bonaccorsi L; Muratori M; Marchiani S; Forti G; Baldi E Mol Cell Endocrinol; 2006 Feb; 246(1-2):157-62. PubMed ID: 16376012 [TBL] [Abstract][Full Text] [Related]
19. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells. Sadar MD; Gleave ME Cancer Res; 2000 Oct; 60(20):5825-31. PubMed ID: 11059779 [TBL] [Abstract][Full Text] [Related]
20. Potent antiandrogen and androgen receptor activities of an Angelica gigas-containing herbal formulation: identification of decursin as a novel and active compound with implications for prevention and treatment of prostate cancer. Jiang C; Lee HJ; Li GX; Guo J; Malewicz B; Zhao Y; Lee EO; Lee HJ; Lee JH; Kim MS; Kim SH; Lu J Cancer Res; 2006 Jan; 66(1):453-63. PubMed ID: 16397261 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]